Search clinical trials for: HH-003 NrtIs

Total 2575 results

Washington University School of Medicine
Wugen, Inc.

Recruiting

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Acute Myeloid Leukemia | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult T Cell Leukemia | Adult T Cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | T-Cell Non-Hodgkin... and other conditions

United States
Wellmarker Bio
Covance

Recruiting

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor

Korea, Republic of, Australia
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
ICM Co. Ltd.

Enrolling by invitation

A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Osteoarthritis, Knee

Australia
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Terminated

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

COVID-19

China
Seelos Therapeutics, Inc.

Terminated

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia (STRIDES)

Spinocerebellar Ataxia Type 3

United States, Spain, Korea, Republic of, Australia, United Kingdom, Brazil, Germany, Portugal
Nacuity Pharmaceuticals, Inc.
Foundation Fighting Blindness

Active, not recruiting

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (SLO RP)

Usher Syndromes

Australia
Alumis Inc

Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Czechia
Anebulo Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

Acute Cannabinoid Intoxication

Netherlands
Hutchmed

Completed

Fruquintinib Renal Impairment Study

Renal Impairment

United States
Bloom Science

Completed

A Phase Ia Safety and Tolerability Study of BL-001

Healthy Volunteers

Switzerland
Alpine Immune Sciences, Inc.

Completed

A Study of ALPN-303 in Adult Healthy Volunteers (RUBY-1)

Healthy Volunteers

Australia
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Netherlands, United Kingdom, Czechia, Portugal, Hungary
RBP4 Pty Ltd
Belite Bio, Inc

Completed

Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85

Healthy Volunteer | Dry Age-related Macular Degeneration

Australia
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Perianal Fistula

Rectal Fistula
Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
Cure Rare Disease, Inc
University of Massachusetts, Worcester

Active, not recruiting

Treatment of a Single Patient With CRD-TMH-001

Duchenne Muscular Dystrophy

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Scar Prevention

United States
Novo Nordisk A/S

Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Anemia

United States
Intra-Cellular Therapies, Inc.

Terminated

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Agitation in Dementia, Including Alzheimer's Disease

United States
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
pH Pharma

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

Otherwise Healthy Overweight or Obese

United States
RBP4 Pty Ltd
Belite Bio, Inc

Completed

Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses

Healthy Volunteer

Australia
Olympus Corporation

Terminated

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Emphysema

Japan
Prof. Dr. Dieter Willbold
Medical University of Vienna; Alzheimer's Association; Helmholtz-Gemeinschaft... and other collaborators

Completed

MAD Phase I Study to Investigate Contraloid Acetate

Alzheimer Disease | Alzheimer Dementia

Germany
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

Healthy Subjects

Germany
Intra-Cellular Therapies, Inc.

Completed

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Healthy | Growth Hormone Disorder

Germany
Argos Therapeutics

Completed

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

HIV Infection

United States, Canada
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Hypertriglyceridemia | Hyperlipoproteinemia Type I | Lipoprotein Lipase Deficiency, Familial | Chylomicronemia, Familial

Canada
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hyperlipidemias | Hypertriglyceridemia

United States
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Chronic Pain
Amgen

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Osteoarthritis
Xenon Pharmaceuticals Inc.

Completed

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Inherited Erythromelalgia | Primary Erythromelalgia

United States
Xenon Pharmaceuticals Inc.

Completed

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Inherited Erythromelalgia | Primary Erythromelalgia

Netherlands
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Hutchison Medipharma Limited

Terminated

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

United States
Rhodes Pharmaceuticals, L.P.
Purdue Pharma, Canada

Completed

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

ADHD

United States, Canada
Takeda

Completed

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

Dengue Fever

Thailand
Corvus Pharmaceuticals, Inc.

Terminated

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Covid-19

United States, Colombia, Spain, Canada, Peru, Brazil, Italy, Argentina, Chile, Germany, Mexico, Ukraine
CinPhloro Pharma, LLC

Recruiting

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Irritable Bowel Syndrome With Diarrhea

United States
Peking Union Medical College Hospital

Not yet recruiting

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

Primary Sjögren Syndrome
Peking Union Medical College Hospital

Recruiting

68Ga-P16-093 PET/CT Imaging in Glioma Patients

Glioma

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Fab'entech

Recruiting

Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

COVID-19

Greece
Inmagene LLC

Active, not recruiting

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

Healthy Volunteers

Australia
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
BioMimetix JV, LLC

Terminated

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

Acne Vulgaris

United States

Search clinical trials for: HH-003 NrtIs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations